Kornimate/medical-research-clean huggingface dataset:
a study of jnj-89853413 for relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms

Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Neoplasms

Summary: the purpose of part 1 (dose escalation) of the study is to assess the safety and tolerability, and to identify the recommended phase 2 dose\[s\] (rp2d\[s\]) in participants with relapsed or refractory (r/r) acute myeloid leukemia (aml) (that is a type of blood cancer that has come back after treatment/or has stopped responding to treatment) or r/r higher-risk type of myelodysplastic neoplasms (mds, type of blood cancer). the purpose of part 2 (cohort expansion) is to further assess the safety, tolerability and efficacy in participants with r/r aml or higher-risk types of mds.


Eligibility criteria:
inclusion criteria: * have a diagnosis, per world health organization (who) 2022 criteria of: 1. relapsed/refractory acute myeloid leukemia (aml) 2. relapsed/refractory moderate high, high, or very high risk myelodysplastic neoplasms (mds) per molecular international prognostic scoring system (ipss-m) * body weight greater than or equals to (\>=) 40 kilograms (kg) * have an eastern cooperative oncology group (ecog) performance status of 0 - 2 * have adequate renal function defined as chronic kidney disease epidemiology collaboration (ckd-epi) estimated glomerular filtration rate (egfr) \>=40 milligrams per minute (ml/min) * participants must have laboratory parameters in the required range exclusion criteria: * has a medical history of clinically significant pulmonary compromise, particularly the need for current supplemental oxygen use to maintain adequate oxygenation * has evidence of an uncontrolled systemic viral, bacterial, or fungal infection * has known allergies, hypersensitivity, or intolerance to the excipients of jnj-89853413 * had major surgery or had significant traumatic injury within 14 days of planned first dose of jnj-89853413 * has known active central nervous system involvement
continuous venovenous hemodiafiltration versus sustained low-efficiency hemodialysis for critically ill patients with acute kidney injury in intensive care unit

Conditions: Acute Kidney Injury

Summary: the investigators conducted a comparison trial between sled and crrt in critically ill patients to evaluate the outcome for all cause mortality at 30 day . the secondary outcome were recovery of renal function, complications during therapy and duration of hospitalization.

the investigators performed a single center experience accumulated over 12 months since february 2009 with a continuous venovenous hemodiafiltration (cvvhdf) and hybrid technique named sustained low-efficiency dialysis (sled). the primary end point was death from any cause by day 30. intensive care unit (icu) patients were eligible for inclusion when serum creatinine was \> 2 mg/dl, and renal replacement therapy (rrt) was initiated. the selected patients were treated with cvvhdf or sled.

Eligibility criteria:
inclusion criteria: - the inclusion criteria were 1. aki requiring rrt 2. hemodynamic instability defined by systolic blood pressure ≤ 90 mmhg and/or diastolic blood pressure ≤ 60 mmhg 3. patients requiring initiation to vasopressor support exclusion criteria: * patients with pre-existing chronic kidney disease ( egfr less than 30 mlmin/1.73m2) were excluded
a vi-0521 study to evaluate the long-term safety and efficacy in type 2 diabetic adults

Conditions: Diabetes

Summary: the purpose of the study is to determine the long-term safety and efficacy of vi-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in type 2 diabetic adults. continuation of initial 6 month trial.


Eligibility criteria:
inclusion criteria: * have completed the qualifying ob-202 trial * if females of child-bearing potential, subjects must be using adequate contraception * provide written informed consent * be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures exclusion criteria: * subjects who have developed one or more morbidities during the ob-202 trial that would pose a safety concern

Keywords: diabetes type 2 diabetes diabetes mellitus metabolic diseases glucose metabolism disorders glycemic control
use of virtual reality for procedural planning of transcatheter aortic valve replacement

Conditions: Aortic Stenosis, Severe

Summary: this study sought to evaluate the impact of virtual reality (vr) tools in procedural planning of transcatheter aortic valve replacement (tavr).

a prospective study involving 11 patients referred for tavr was conducted. a multidetector computed tomography (mdct) was used to acquire and segment the anatomy of the access route and landing zone. from the information obtained with the mdct in dicom format, the investigators built a virtual platform (visuamed, teacher team. valencia. spain) that contains all the clinical information of the patients and a virtualized model of their anatomy. wearing vr devices, the professional was able to "walk inside " the anatomy in an interactive and immersive way. decisions after the evaluation of routine clinical images were compared with those after experience with vr models and intraprocedural findings.

Eligibility criteria:
inclusion criteria: * severe aortic stenosis considered for tavr procedure at a single institution exclusion criteria: * none
contrast enhanced transrectal ultrasonography (trus) to assess prostatic vascularity after radiotherapy (xrt)

Conditions: Prostate Cancer

Summary: solid tumors, including prostate cancer, commonly exhibit tumor-associated neovascularity (growth of new blood vessels to feed the tumor) with increased microvessel density. systemic, hormonal, and radiotherapy treatments typically decrease or suppress tumor - associated vascularity through several mechanisms, including apoptosis (process of cell death) and anti-angiogenic pathways (ways to destroy new blood vessel growth). previously at the investigators' center, they have demonstrated that increased prostatic vascularity (blood vessels defined to prostate) detected ultrasonographically correlated with disease free survival after radical prostatectomy (surgical removal of entire prostate), and may be indicative of higher grade, higher stage disease. the significance of prostate neovascularity in response to treatment with external beam radiotherapy (ebrt) (standard of care) has not been well studied. the investigators hypothesize that prostate cancer that recurs after radiotherapy may exhibit measurable patterns of tumor-associated vascularity, which may represent a minimally invasive marker of cancer stage, grade and response to treatment. the investigators propose a pilot study to assess the feasibility of serial enhanced transrectal ultrasonography (trus) examinations during and after radiotherapy for prostate cancer.


Eligibility criteria:
inclusion criteria: * men aged 40 - 80 years old * biopsy proven intermediate/high risk clinically localized prostate cancer, as determined by a gleason score of 7 or higher, clinical stage t2b or higher, or psa \> 10. pathology will be confirmed by at least two reviews * patients opting for ebrt (external beam radiation therapy, standard of care) without hormonal ablation * ability to undergo serial trus procedures * ability to give informed consent exclusion criteria: * subject has known hypersensitivity to octafluoropropane. * evidence of distant metastatic disease on staging evaluation * previous treatment for prostate cancer, including any form of androgen ablation * previous procedures involving the anus or rectum, making serial trus difficult or dangerous * expected life expectancy less than 10 years * baseline testosterone \< 200 ng/dl * subject with cardiac shunts and elevated pulmonary hypertension * subject has worsening or clinically unstable congestive heart failure. * subject has acute myocardial infarction or acute coronary syndrome. * subject has ventricular arrhythmias or is high risk for arrhythmias. * subject has respiratory failure, severe emphysema or pulmonary emboli. * subject has a history of cardiac shunt or pulmonary hypertension.

Keywords: prostate cancer prostatic vascularity external beam radiation treatment contrast enhanced transrectal ultrasound
the effect of resistance exercise on inflammation in young and older adults

Conditions: Aging; Inflammatory Response

Summary: healthy young and older adults will complete two trials in a randomized crossover counter-balanced order, including resistance exercise and sedentary control. during each trial, blood samples will be collected. the investigators hypothesized that an acute bout of resistance exercise exert different inflammation responses in young and older adults.


Eligibility criteria:
inclusion criteria: * age: 20-80 * healthy male * without experience of resistance training exclusion criteria: * no acute or chronic musculoskeletal symptoms * smoking * alcohol or drug abuse * fail to conduct resistance exercise
the relationship between fetal baseline heart-rate and the level of acetyl-choline esterase in fetal blood

Conditions: Fetal Heart Failure (Disorder)

Summary: pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. data regarding maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be collected. a blood sample will be acquired from the parturient and the umbilical cord as well as a sample from the placenta will be obtained. levels of acetyl choline esterase (ache) will be determined from all aforementioned samples. statistical correlation between fetal baseline heart rate and fetal and maternal ache levels will be assessed.

pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. after signing an informed consent, data regarding maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be collected. patients will be divided into 2 equal groups according to fetal baseline heart rate: 1. st group-fetal heart rate between 110-130 beats per minute (bpm). 2. nd group-fetal heart rate between 140-160 bpm. a blood sample will be acquired from the parturient and the umbilical cord as well as a sample from the placenta will be obtained. levels of acetyl choline esterase (ache) will be determined from all aforementioned samples. statistical correlation between fetal baseline heart rate and fetal and maternal ache levels will be assessed. data regarding demographic, medical and obstetric information of the participants will be obtained from the hospital's electronic records.

Eligibility criteria:
inclusion criteria: * pregnant women between 32 and 41 weeks' gestation undergoing either vaginal or cesarean delivery with a fetal baseline heart rate of 110-130 beats per minute and 140-160 beats per minute. exclusion criteria: 1. delivery before 32 weeks of gestation 2. maternal bradycardic (\ 100) resting heart rate. 3. fetal bradycardia (\ 160). 4. suspected chorioamnionitis 5. maternal diseases which can affect her heart rate such as: 1. cardiac disease (including arrhythmias) 2. diseases of the thyroid gland 3. rheumatic diseases 6. use of medication which alters heart rate such as: 1. beta blockers 2. beta agonists 3. cocaine, amphetamines 7. use of pethidine and phenergan during delivery
national registry and cohort study of pulmonary vascular disease

Conditions: Pulmonary Arterial Hypertension

Summary: this is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (ph). the purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with ph；also to set up registration system of ph in china, to build a database of chinese ph, to establish a web-based international standard data acquisition system for ph and a multicenter clinical research platform. the results of the study will provide a basis for the future national health policy for prevention and treatment of ph.


Eligibility criteria:
inclusion criteria: * newly diagnosed or previously diagnosed patients with ph. * documentation of mean pulmonary arterial pressure (mpap) \>20 mm hg by right heart catheterization, performed at any time prior to study enrollment. exclusion criteria: * have not had documentation of hemodynamic criteria for ph by right heart catheterization at some time preceding study entry and following development of symptoms associated with ph. * do not meet the required hemodynamic criteria for entry into the study.
vascular and metabolic effects of vytorin vs simvastatin

Conditions: Hypercholesterolemia

Summary: the investigators hypothesize that vytorin will improve insulin resistance compared with simvastatin


Eligibility criteria:
inclusion criteria: * hypercholesterolemic patients (ldl cholesterol levels\>100 mg/dl) exclusion criteria: * overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (hba1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Keywords: insulin resistance
prospective study of heart failure with preserved left ventricular ejection fraction

Conditions: Congestive Heart Failure; Left Ventricular Ejection Fraction; Heart Failure With Preserved Ejection Fraction

Summary: the purpose of this study is to examine electrical and echocardiographic characteristics and prognosis of consecutive patients admitted with acute heart failure and diagnosed to have heart failure with preserved ejection fraction (hfpef).

* time 0: patients will be screened at the time of presentation to the hospital at participating centres * usually patients will be hospitalised for an acute dyspnea in relation with a pulmonary congestion. this congestion does not necessarily justify a hospitalization and for part of the patients a consultation and a dedicated treatment would be good enough to cure the symptoms. * thus, patients seen in emergency for a congestion and diagnosed or known to have a preserved left ventricular ejection fraction (lv ef \> 45%) will be proposed to participate to the study. * patients meeting inclusion criteria will be invited back to the clinic in stable condition, approximately 4-8 weeks after the initial hospitalization. * time 4-8 weeks after initial hospitalisation (not after discharge): comprehensive history-taking and examinations. * any information necessary for the study will be collected by the principal investigator in each participating center in a dedicated, secure, e-crf. the access to the e-crf will be restrictive to the only principal investigator of each center. the lonely other persons able to take look to the e-crf are the study monitors. * time 6, 12, and 18 months: follow up by phone call or review of charts or other records such as death registries. this part of the study will be performed by the cras in the french society of cardiology

Eligibility criteria:
inclusion criteria: * patient presenting to the hospital with congestive heart failure, defined as: 1. clinical signs of heart failure major criteria * paroxysmal nocturnal dyspnea * orthopnea * jugular venous distension * pulmonary crackling rales * 3rd heart sound * cardiothoracic ratio \> 0.5 on x-ray * pulmonary oedema on x-ray minor criteria * peripheral oedema * nocturnal cough * dyspnoea at exercise * hepatomegaly * pleural effusion * tachycardia (defined as ≥ 100 beats per minute) heart failure if: presence of 2 major criteria or 1 major + 2 minor criteria 2. lvef ≥ 45% by echocardiography within 72h 3. bnp \> 100 ng/l or nt-probnp \> 300 ng/l exclusion criteria: * evidence of primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease * known cause of right heart failure not related to left ventricular dysfunction * pericardial constriction * clinically significant pulmonary disease, as evidenced by requirement of home oxygen. * end-stage renal disease requiring dialysis * bi-ventricular pacemaker (crt)

Keywords: heart failure ejection fraction echocardiography
effects of pre-event massage over the neuromuscular response

Conditions: Neuromuscular Diseases

Summary: the study observes the effect of a pre-event massage on the gastrocnemius muscles over the neuromuscular response of the gastrocnemious muscles.


Eligibility criteria:
exclusion criteria: * muscle injury in the last two months * to not understand the study orders * suffer a musculoskeletal disorder that doesn't allow the subject to do the study protocol

Keywords: neuromuscular response pre-competition massage pre-event massage
nanodisk-ms assay for the diagnosis of active pulmonary and extrapulmonary tuberculosis in hospitalized patients

Conditions: Active Tuberculosis; Tuberculosis, Extrapulmonary; Tuberculosis, Pulmonary

Summary: diagnosis and treatment of tuberculosis are often delayed in hospitalized patients, leading to worse outcomes. rapid diagnosis of tuberculosis currently relies on microscopy and molecular techniques, which have limitations including low sensitivity and high cost.highly sensitive diagnostic technique is needed for more accurate rapid diagnosis of tuberculosis to aid earlier initiation of antituberculous therapy. detection of mycobacterium tuberculosis (mtb) antigens in the bloodstream can potentially allow early diagnosis of tuberculosis. this study aims to evaluate the diagnostic performance of a novel assay using nanotechnology to detect mtb antigens in patients admitted to hospital with suspected pulmonary and/or extrapulmonary tuberculosis. blood will be taken from eligible patients, and will be sent to the school of biological and health systems engineering, arizona state university, for detection of 10-kda culture filtrate protein (cfp-10) and the 6 kda early secretory antigenic target (esat-6), two antigens specific for mtb, using the nanodisk-ms assay. investigations, including microscopy, culture, mtb polymerase chain reaction (pcr), and imaging, will be performed for diagnosis of tuberculosis. the diagnostic performance of nanodisk-mass spectrometry (ms) assay will be evaluated.


Eligibility criteria:
inclusion criteria: * adult patients aged 18 or above, * assessed by an infectious diseases physician to have clinical and/or radiological suspicion of pulmonary and/or extrapulmonary tb. exclusion criteria: * refusal to consent from patients or next of kins for incompetent patients.
positive er expression assessed by 18f-fes pet/ct in the mbc with er-negative primary tumor

Conditions: Breast Cancer

Summary: to investigate the treatment pattern and efficacy of patients with negative primary er lesion but positive er expression in mbc using a novel convenient way of 18f-fluoroestradiol positron emission tomography/computed tomography (18f-fes pet/ct).


Eligibility criteria:
inclusion criteria: * patients diagnosed with breast cancer (according to international classification of diseases 10th revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a nonmetastatic stage. * mbc patients who underwent 18f-fes pet/ct at the fudan university shanghai cancer center between 2012 and 2023 * patients diagnosed with primary er-negative tumor and who were yet to receive any systemic therapy during the advanced stage exclusion criteria: patients with incomplete medical records and those diagnosed with secondary primary tumors
development and preliminary testing of a "papageno"-story interview intervention- aim 3

Conditions: Suicide Prevention

Summary: the purpose of this study is to determine the effects of a short "papageno story" video of a compilation of interviews on proximal risk factors for suicide. the researchers believe that the intervention may increase protective factors related to suicide.


Eligibility criteria:
inclusion criteria: * people who are part of an existing cohort within designxm * they will also answer yes to the question: "in the past 1 year, have you wished you were dead or wished you could go to sleep and not wake up?" exclusion criteria: * no exclusions if all inclusion criteria is met
rectal indomethacin to prevent post eswl-pancreatitis

Conditions: Pancreatitis

Summary: the purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-eswl pancreatitis.

it is a prospective, double-blind, randomized controlled trial. patients with painful chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) who are treated with eswl at changhai hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.

Eligibility criteria:
inclusion criteria: * any patient with chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) undergoing p-eswl * at least 18 years old * provides informed consent exclusion criteria: * readmitted to the hospital during the enrollment of the study * contraindications to eswl * suspected or established malignancy * pancreatic ascites * receiving nsaids within 7 days * contraindication to nsaids (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine \>120 μmol/l) * presence of coagulopathy or received anticoagulation therapy within 3 days * acute pancreatitis within 3 days * known active cardiovascular or cerebrovascular disease * pregnant or breastfeeding women * without a rectum (ie, status post-total proctocolectomy)

Keywords: extracorporeal shock wave lithotripsy(eswl) prophylaxis indomethacin chronic pancreatitis